Sun Pharma shares rose 0.87% despite a 36.4% year-on-year drop in September-quarter net profit to ₹1,988.5 crore. Revenue increased 11.9% to ₹16,198.7 crore, driven by India and innovative medicines, while exceptional US litigation and Organon acquisition costs weighed on earnings.
Sun Pharma shares rose 0.87% despite a 36.4% year-on-year drop in September-quarter net profit to ₹1,988.5 crore. Revenue increased 11.9% to ₹16,198.7 crore, driven by India and innovative medicines, while exceptional US litigation and Organon acquisition costs weighed on earnings.
<iframe src="https://hindustansphere.com/embed/cluster/a47031fab334d6079d4b22e78453204ce15c0e42" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Sun Pharma shares gain despite Q2 profit slips 36% YoY | Should you buy, sell or hold? What brokerage says, target price"></iframe>
